Filing Details

Accession Number:
0001479290-23-000102
Form Type:
4
Zero Holdings:
No
Publication Time:
2023-09-07 17:37:42
Reporting Period:
2023-09-05
Accepted Time:
2023-09-07 17:37:42
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1479290 Revance Therapeutics Inc. RVNC Pharmaceutical Preparations (2834) 770551645
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1803375 Dwight Moxie C/O Revance Therapeutics, Inc
1222 Demonbreun Street, 20Th Floor
Nashville TN 37203
Svp, Gc & Secretary No Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Disposition 2023-09-05 23,853 $17.81 55,066 No 4 S Direct
Common Stock Disposition 2023-09-06 11,000 $17.06 44,066 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 S Direct
No 4 S Direct
Footnotes
  1. The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan dated June 05, 2023 by Mr. Moxie.
  2. The price reported in Table 1, Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $17.44 to $18.20. Mr. Moxie undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
  3. The price reported in Table 1, Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $16.80 to $17.52. Mr. Moxie undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.